Literature DB >> 22149181

Short communication: Increased expression of secretory leukocyte protease inhibitor in oral mucosa of Colombian HIV type 1-exposed seronegative individuals.

Natalia Taborda1, Wildeman Zapata-Builes, Carlos Montoya, María Teresa Rugeles.   

Abstract

The exposure to human immunodeficiency virus type 1 (HIV-1) does not always result in infection. Indeed, there are individuals who have been repeatedly exposed to HIV-1 but do not exhibit clinical or serological evidence of infection; they are known as HIV-exposed seronegative individuals (HESN). To determine if secretory leukocyte protease inhibitor (SLPI), a soluble factor secreted by epithelial cells lining mucosal surfaces that showed anti-HIV activity in vitro, was associated with natural resistance to HIV infection, we measured by real time RT-PCR the expression of SLPI in oral mucosa of a cohort of Colombian HESN, in chronically HIV-1-infected individuals and in healthy controls. The HESN expressed significantly higher levels of SLPI mRNA than healthy controls (p=0.033) and chronically infected subjects (p=0.011). These findings suggest an association between SLPI expression and the natural resistance to HIV-1 infection exhibited by our HESN cohort.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22149181      PMCID: PMC3423646          DOI: 10.1089/AID.2011.0151

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  21 in total

1.  HIV-1 exposed uninfected men who have sex with men have increased levels of salivary CC-chemokines associated with sexual behavior.

Authors:  Klara Hasselrot; Göran Bratt; Kristina Duvefelt; Taha Hirbod; Eric Sandström; Kristina Broliden
Journal:  AIDS       Date:  2010-06-19       Impact factor: 4.177

2.  Cervicovaginal levels of lactoferrin, secretory leukocyte protease inhibitor, and RANTES and the effects of coexisting vaginoses in human immunodeficiency virus (HIV)-seronegative women with a high risk of heterosexual acquisition of HIV infection.

Authors:  Richard M Novak; Betty A Donoval; Parrie J Graham; Lucy A Boksa; Gregory Spear; Ronald C Hershow; Hua Yun Chen; Alan Landay
Journal:  Clin Vaccine Immunol       Date:  2007-08-01

Review 3.  [Soluble factors with inhibitory activity against type 1 Human Immunodeficiency Virus].

Authors:  Wildeman Zapata; Carlos Julio Montoya; María Teresa Rugeles
Journal:  Biomedica       Date:  2006-09       Impact factor: 0.935

Review 4.  Secretory leukocyte protease inhibitor and elafin/trappin-2: versatile mucosal antimicrobials and regulators of immunity.

Authors:  Jean-Michel Sallenave
Journal:  Am J Respir Cell Mol Biol       Date:  2010-04-15       Impact factor: 6.914

5.  Secretory leukocyte protease inhibitor in vaginal fluids and perinatal human immunodeficiency virus type 1 transmission.

Authors:  K Pillay; A Coutsoudis; A K Agadzi-Naqvi; L Kuhn; H M Coovadia; E N Janoff
Journal:  J Infect Dis       Date:  2001-01-18       Impact factor: 5.226

6.  Expression of secretory leukocyte protease inhibitor in middle ear cholesteatoma.

Authors:  Jung-Kyu Lee; Sung-Won Chae; Jae-Gu Cho; Heung-Man Lee; Soon-Jae Hwang; Hak-Hyun Jung
Journal:  Eur Arch Otorhinolaryngol       Date:  2006-07-26       Impact factor: 2.503

7.  Increased levels of human beta-defensins mRNA in sexually HIV-1 exposed but uninfected individuals.

Authors:  Wildeman Zapata; Benigno Rodriguez; Jan Weber; Hernando Estrada; Miguel E Quiñones-Mateu; Peter A Zimermman; Michael M Lederman; Maria T Rugeles
Journal:  Curr HIV Res       Date:  2008-11       Impact factor: 1.581

8.  HIV-1 neutralizing activity is correlated with increased levels of chemokines in saliva of HIV-1-exposed uninfected individuals.

Authors:  Taha Hirbod; Camilla Reichard; Klara Hasselrot; Johan Söderlund; Joshua Kimani; Job J Bwayo; Francis Plummer; Rupert Kaul; Kristina Broliden
Journal:  Curr HIV Res       Date:  2008-01       Impact factor: 1.581

9.  Salivary secretory leukocyte protease inhibitor is associated with reduced transmission of human immunodeficiency virus type 1 through breast milk.

Authors:  Carey Farquhar; Thomas C VanCott; Dorothy A Mbori-Ngacha; Lena Horani; Rose K Bosire; Joan K Kreiss; Barbra A Richardson; Grace C John-Stewart
Journal:  J Infect Dis       Date:  2002-09-20       Impact factor: 5.226

Review 10.  Not just sheer luck! Immune correlates of protection against HIV-1 infection.

Authors:  Luca Piacentini; Claudio Fenizia; Valentina Naddeo; Mario Clerici
Journal:  Vaccine       Date:  2007-12-18       Impact factor: 3.641

View more
  1 in total

1.  High Expression of Antiviral and Vitamin D Pathway Genes Are a Natural Characteristic of a Small Cohort of HIV-1-Exposed Seronegative Individuals.

Authors:  Wbeimar Aguilar-Jimenez; Irma Saulle; Daria Trabattoni; Francesca Vichi; Sergio Lo Caputo; Francesco Mazzotta; Maria T Rugeles; Mario Clerici; Mara Biasin
Journal:  Front Immunol       Date:  2017-02-13       Impact factor: 7.561

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.